Skip to main content
Premium Trial:

Request an Annual Quote

Informax Gets $10 Million from Amersham Pharmacia

NEW YORK, Sept 6  Amersham Pharmacia Biotech said on Wednesday it had invested $10 million in InforMax and also announced a strategic collaboration with the bioinformatics company.

The deal represents the largest collaboration for InforMax of Rockville, Md., to date.

Under the terms of the deal Amersham, the Piscataway, N.J.-based life sciences division of Nycomed Amersham (NYSE: NYE; LSE: NAM), and InforMax will work together to expand the capability of InforMax’s GenoMax bioinformatics product.

The companies plan on creating a data analysis system that will allow pharmaceutical companies to merge and analyze genomics, pharmacogentics, proteomics and drug screening data.

The companies will share the proceeds from marketing and distributing the new product.

“Our goal is to expand our bioinformatics business by integrating our diverse high throughput platforms into a higher value proposition for our pharmaceutical industry customers,” Andrew Whiteley, vice president of bioinformatics at Amersham Pharmacia Biotech, said in a statement.

Amersham could not immediately be reached for comment.

A spokesman for InforMax declined to comment on the deal, saying the company is in a quiet period in the run up to its planned initial public offering on the Nasdaq.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.